Physician profile
Edward C Kim
NPI 1275538076
$4,994.76
in general payments reported to CMS, 2019-2025
31 companies · $763 in 2025
The $763 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $446 · 2021: $954 · 2022: $506 · 2023: $597 · 2024: $834 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173 · Education: $20.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.94 |
| Education | $20.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,046.10 | 2019-2025 | |
| Braintree Laboratories, INC. | $572.20 | 2020-2021 | |
| Janssen Biotech, INC. | $489.32 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $411.20 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $402.60 | 2019-2025 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $347.29 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $320.23 | 2019-2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $223.23 | 2023-2024 | Dupixent |
| Celgene Corporation | $222.10 | 2021-2024 | Zeposia |
| Ethicon US, LLC | $130.30 | 2019-2024 | Linx Reflux Management System |
| Janssen Scientific Affairs, LLC | $109.10 | 2021 | |
| Lilly USA, LLC | $79.49 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $73.38 | 2019 | |
| Madrigal Pharmaceuticals | $71.12 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $56.45 | 2024-2025 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $47.73 | 2023-2025 | |
| Celltrion USA INC. | $47.62 | 2024-2025 | Vegzelma, Zymfentra |
| Amgen INC. | $42.34 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $40.17 | 2025 | Zenpep |
| Daiichi Sankyo INC. | $39.76 | 2019 | |
| Merck Sharp & Dohme LLC | $36.18 | 2019-2021 | |
| Novo Nordisk INC | $29.42 | 2025 | Wegovy |
| Allergan, INC. | $22.74 | 2020 | |
| Qol Medical, LLC | $19.83 | 2025 | Sucraid |
| Nestle Healthcare Nutrition INC. | $19.34 | 2023 | |
| Medtronic, INC. | $18.44 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.97 | 2023 | Givlaari |
| Gilead Sciences, INC. | $15.59 | 2019 | |
| Alfasigma USA, INC. | $14.97 | 2020 | |
| Dynavax Technologies Corporation | $14.92 | 2023 | Heplisav-B |
| Ironwood Pharmaceuticals, INC | $13.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.